Blood advances最新文献

{"title":"CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma.","authors":"Rahul Banerjee","doi":"10.1182/bloodadvances.2026019898","DOIUrl":"10.1182/bloodadvances.2026019898","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6582-6584"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.","authors":"Abiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, Madhu Nagaraj, Sukriti Seth, Francis K Buadi, Suzanne R Hayman, Morie A Gertz, Angela Dispenzieri, Eli Muchtar, Prashant Kapoor, Wilson Gonsalves, Taxiarchis Kourelis, David Dingli, Rahma Warsame, Nelson Leung, Joselle Cook, Moritz Binder, Yi Lin, Lisa Hwa, Michelle G Rogers, Miriam Hobbs, Amie Fonder, Dragan Jevremovic, S Vincent Rajkumar, Shaji K Kumar","doi":"10.1182/bloodadvances.2026020294","DOIUrl":"10.1182/bloodadvances.2026020294","url":null,"abstract":"<p><strong>Abstract: </strong>Measurable residual disease (MRD) is a powerful prognostic tool in multiple myeloma, but predictors of achieving MRD negativity after autologous stem cell transplantation (ASCT) are not well defined. We studied 814 patients who achieved at least a very good partial response after ASCT between January 2016 and January 2023 and underwent MRD assessment by next-generation flow cytometry. Overall, 387 (48%) achieved MRD negativity after ASCT. The presence of t(11;14) (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.4-3.2; P< .01) and pretransplant response less than complete remission (OR, 2.1; 95% CI, 1.2-3.7; P< .01) independently predicted MRD positivity. Patients who were MRD positive had inferior progression-free survival (PFS; hazard ratio [HR], 1.99; 95% CI, 1.53-2.58; P< .001) and overall survival (HR, 1.62; 95% CI, 1.10-2.28; P = .009). Despite lower MRD-negative rate, 5-year PFS was similar among t(11;14) MRD positive (58%) and patients who were MRD negative (63%; P = .12). In patients who were MRD negative, the 5-year PFS was 73% in those without ≥2 HRCA compared with 55% in those with ≥2 HRCA (HR 1.9, 95% CI 1.2-3.3; P = .01). In the MRD-positive cohort, 5-year PFS was 53% in patients without ≥2 HRCA vs 17% in those with ≥2 HRCA (HR, 2.4; 95% CI, 1.6-3.6; P< .01). In addition, higher residual clonal plasma cell burden within MRD-positive disease was associated with inferior PFS (HR, 2.4; 95% CI, 1.2-6.9; P = .002). This study highlights that the presence of t(11;14) independently predicts MRD positivity after ASCT, although it does not significantly affect prognosis in this subgroup.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6694-6702"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world investigation of germ line predisposition to myelodysplastic syndromes.","authors":"Anna Tranberg, Maria Creignou, Teresa Mortera Blanco, Elsa Bernard, Ann-Charlotte Björklund, Mikaela Hillberg Widfeldt, Indira Barbosa, Matilda Kjellander Kynning, David Cabrerizo Granados, Vanessa Lundin, Johanna Ungerstedt, Gabriele Todisco, Elli Papaemmanuil, Eva Hellström Lindberg, Bianca Tesi","doi":"10.1182/bloodadvances.2026019942","DOIUrl":"10.1182/bloodadvances.2026019942","url":null,"abstract":"<p><strong>Abstract: </strong>Follow-up of potential germ line variants revealed by diagnostic targeted sequencing (TS) for myelodysplastic syndromes (MDS) has been proposed by clinical guidelines. However, their feasibility and clinical yield in routine MDS practice remain uncertain. We evaluated the real-world applicability of systematic germ line follow-up in an unselected cohort of 716 patients (median age, 74 years) evaluated for MDS. Their diagnostic TS data were analyzed to identify variants in CEBPA, DDX41, ETV6, GATA2, and RUNX1 with a variant allele frequency of ≥35%. In total, 98 variants were identified in 87 (12.2%) patients. Germ line investigation was possible for 62 patients; for the remaining 25 without biobanked material, medical charts were reviewed. We identified pathogenic/likely pathogenic (P/LP) germ line variants in 19 patients (2.7%). Most P/LP variants were found in DDX41 (73.7%), followed by 10.5%, 10.5%, and 5.3% in RUNX1, GATA2, and ETV6, respectively, with germ line conversion rates between 5.4% and 93.3%. Patients with P/LP variants had a median age at diagnosis of 73 years, with male predominance (3.75:1). Most patients were diagnosed with MDS-excess blasts-1 (MDS-EB1) or MDS-EB2 (68.4%) and had normal cytogenetics (95%). A review of medical charts in younger patients (aged <50 years) revealed germ line predisposition in other genes in an additional 5 patients, revisiting the prevalence of predisposition to 3.4% overall and to 16.7% in those aged <50 years. Our results show that systematic germ line follow-up after diagnostic TS succeeds in identifying predisposition in nearly 3% of patients at a typical adult MDS clinic. Germ line testing for genes not routinely assessed by diagnostic TS is required in younger patients.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6742-6753"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826).","authors":"Sairah Ahmed, Hongli Li, Alex F Herrera, Anamarija M Perry, Alexandra E Kovach, Sarah C Rutherford, Kelly Davison, Sharon M Castellino, Andrew M Evens, Brad Kahl, Nancy L Bartlett, John P Leonard, Margaret A Shipp, Sonali M Smith, Kara M Kelly, Michael LeBlanc, Jonathan W Friedberg, Joo Y Song","doi":"10.1182/bloodadvances.2026021402","DOIUrl":"10.1182/bloodadvances.2026021402","url":null,"abstract":"<p><strong>Abstract: </strong>Classic Hodgkin lymphoma (cHL) associated with Epstein-Barr virus (EBV) positive status as well as nonnodular sclerosis (non-NS) histologic subtypes has demonstrated poorer outcomes compared with EBV- and NS tumors. We report a prespecified subset analysis of patients enrolled in the phase 3 SWOG S1826 trial to evaluate outcomes based on EBV status and histologic subtype in patients treated with N-AVD (nivolumab-AVD) or BV-AVD (brentuximab vedotin-AVD). In the phase 3 SWOG S1826 trial, patients with stage III to IV cHL were randomized to N-AVD or BV-AVD treatment. Of 970 eligible patients, 522 had known EBV status. N-AVD improved 3-year progression-free survival (PFS) in patients who were EBV+ (91% vs 70%; hazard ratio [HR], 0.30; P = .01) and EBV- (90% vs 84%; HR, 0.64; P = .09). Among 664 patients with slides available for histology review, 102 (15.4%) had non-NS histologic subtypes. N-AVD prolonged 3-year PFS in patients with non-NS histologic subtype (86% vs 63%; HR, 0.33; P = .006) and NS histologic subtype (93% vs 86%; HR, 0.53; P = .01). Non-NS histologic subtype was independently associated with inferior outcomes (HR, 2.54; P< .0001) after adjusting for treatment in the entire cohort. However, N-AVD treatment still had favorable PFS within this high-risk group. In addition, patients with EBV+ status or non-NS histologic subtype cHL treated with BV-AVD had significantly worse PFS (HR, 1.97; P = .03 for EBV and HR, 3.08; P< .0001 for histology). N-AVD substantially abrogated the historically poor prognosis associated with EBV+ status and non-NS histologic subtype in advanced-stage cHL. These results support N-AVD as a frontline standard of care, particularly in high-risk biologic subgroups. This trial was registered at www.clinicaltrials.gov as NCT03907488.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6675-6682"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant.","authors":"Elisabetta Xue, Sanchita Das, Hyoyoung Choo-Wosoba, Dimana Dimitrova, Mustafa A Hyder, Francis A Flomerfelt, Brian Dawson, William Telford, Kalpana Upadhyaya, Kamil A Rechache, Christopher G Kanakry, Jennifer A Kanakry","doi":"10.1182/bloodadvances.2025018166","DOIUrl":"10.1182/bloodadvances.2025018166","url":null,"abstract":"<p><strong>Abstract: </strong>The clinical significance of human herpesvirus 6 (HHV-6) after allogeneic hematopoietic cell transplant (HCT) is debated. We prospectively collected weekly whole-blood HHV-6 in 217 posttransplantation cyclophosphamide (PTCy)-based HCT recipients. Overall, 149 patients (69%) had HHV-6 detected, at a median of 21 days after HCT; in 63 (29%) patients, HHV-6 DNAemia spiked to ≥4 × log10 copies per mL (high-level HHV-6 DNAemia) at median day +27. Hematologic malignancy, myeloablative conditioning, HLA-partially mismatched donor, marrow graft, PTCy dose, and sirolimus use were univariates associated with high-level HHV-6 DNAemia. All spikes precipitously declined spontaneously, but after initial decline, 27% persisted at ≥3 × log10 copies per mL for >1 month. Those with HHV-6 spikes had lower day +28 CD4+ T-cell counts. During initial spikes, there was a strong correlation between plasma and whole-blood HHV-6 DNAemia. By contrast, in patients with HHV-6 persisting for >1 month, HHV-6 was predominantly found within CD4+ T cells but not in plasma. Only 1 patient developed HHV-6-associated encephalitis. High-level HHV-6 DNAemia was associated with significantly increased rates of otherwise unexplained fever (35% vs 21% in patients without high-level HHV-6 DNAemia), rash (27% vs 12%), transaminitis (52% vs 27%), and gastrointestinal symptoms (23% vs 7%), as well as increased risk of acute (36% vs 18%) and moderate-to-severe chronic graft-versus-host disease (GVHD; 22% vs 8%). HHV-6 detection occurs frequently in PTCy recipients but infrequently leads to classic HHV-6-related disease (encephalitis), although it associates with various self-limited clinical symptoms, may play a role in shaping immune reconstitution, and may serve as a marker for increased GVHD risk.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6785-6795"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry.","authors":"Alfonso Iorio, Federico Germini, Quazi Ibrahim, Arun Keepanasseril, Davide Matino, Emma Iserman, Adrienne Lee, Letizia Polito, Katya Moreno, Michelle Santos, Man-Chiu Poon","doi":"10.1182/bloodadvances.2025019430","DOIUrl":"10.1182/bloodadvances.2025019430","url":null,"abstract":"<p><strong>Abstract: </strong>Emicizumab prophylaxis has been approved in Canada for the prevention or reduction of bleeding episodes in people with congenital hemophilia A (PwHA). Using routinely collected health data from the Canadian Bleeding Disorders Registry (CBDR), this observational cohort study aimed to evaluate the long-term safety and effectiveness of emicizumab in PwHA. Deidentified data from the CBDR were collected for PwHA who had received ≥1 dose of emicizumab from 2018 up to 31 December 2023. Intrapatient comparisons of annualized bleeding rates (ABRs) for all reported bleeds before and after emicizumab were performed using a negative binomial regression model. Overall, 710 PwHA received ≥1 emicizumab dose, and 539 (75.9%) had >1 year of emicizumab exposure. During the observational period, the safety profile was in keeping with previous reports; 34 adverse events were observed, including 2 thrombotic events (1 unlikely related to emicizumab; 1 probably related to previous use of eptacog alfa and/or possibly related to previous emicizumab, and associated with a central venous access device). Over a median (first to third quartiles) follow-up time of 549 (374-690) days, 439 (61.8%) PwHA had no recorded bleeds. Mean ABR decreased from 1.00 (95% confidence interval [CI], 0.87-1.14) before emicizumab to 0.47 (95% CI, 0.40-0.55) after emicizumab (rate ratio, 0.47 [95% CI, 0.41-0.55]; P< .001). A notable decrease in bleeds and sustained bleed control were observed in this population for up to a 5-year follow-up period. Continued follow-up will allow for greater quantification of this impact over time, providing valuable information to health care practitioners and regulatory authorities.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6862-6872"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development.","authors":"Joseph Pidala, Betty K Hamilton, George L Chen, Lynn Onstad, Steven Z Pavletic, Paul A Carpenter, Catherine J Lee, Carrie L Kitko, Nosha Farhadfar, Anne M Hall, Jacqueline Mays, Stephanie J Lee","doi":"10.1182/bloodadvances.2026021346","DOIUrl":"10.1182/bloodadvances.2026021346","url":null,"abstract":"<p><strong>Abstract: </strong>The incidence of chronic graft-versus-host disease (GVHD) is declining, but up to 30% of GVHD survivors are still diagnosed with chronic GVHD. We conducted a prospective, multicenter, and observational study to understand the incidence and earliest presenting signs and symptoms of chronic GVHD in the current era to inform trials testing early therapies. Patients were enrolled and assessed before allogeneic hematopoietic cell transplantation (HCT), approximately every 2 months through the first year after HCT, and at the time of chronic GVHD diagnosis. Clinician assessments, patient-reported measures (Lee Symptom Scale [LSS], Patient-Reported Outcomes Measurement Information System), and biologic samples were collected at each time point. A total of 208 subjects were enrolled across 7 HCT centers. The cumulative incidence of any chronic GVHD was 54% by 24 months after HCT, whereas chronic GVHD requiring systemic immunosuppressive therapy (IST) was 38%. At onset, organ involvement included skin (32%), eyes (41%), mouth (42%), liver (17%), gastrointestinal tract (9%), lungs (11%), and joint/fascia (5%), with an overall severity of mild (or less) in 55%, moderate in 37%, or severe in 8% of patients. Management practices were heterogeneous. Subsequent chronic GVHD requiring IST was significantly associated with baseline donor/recipient cytomegalovirus positivity and nonposttransplant cyclophosphamide-based acute GVHD prophylaxis, as well as serial changes in skin/mouth/joint (photographic range of motion) organ scores and the LSS summary score. These data provide current estimates of chronic GVHD incidence and presenting features, new data on risk predictors, and a data resource for future overall and organ-specific biomarker studies. This trial was registered at www.clinicaltrials.gov as NCT04188912.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6852-6859"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CATCHing chronic GVHD.","authors":"Matthias Fante, Daniel Wolff","doi":"10.1182/bloodadvances.2026021901","DOIUrl":"10.1182/bloodadvances.2026021901","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":"10 19","pages":"6850-6851"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burkitt lymphoma: current understanding, unmet needs, and research directions.","authors":"Adiba Khan, Cristina López, Suzanne D Turner, Sam M Mbulaiteye","doi":"10.1182/bloodadvances.2024015620","DOIUrl":"10.1182/bloodadvances.2024015620","url":null,"abstract":"<p><strong>Abstract: </strong>Burkitt lymphoma (BL) is an aggressive B-cell lymphoma historically classified into endemic, sporadic, or immunodeficiency-associated BL based on clinical and epidemiological features. Recent genomic and epigenomic studies have refined this framework, distinguishing Epstein-Barr virus (EBV)-positive and EBV-negative BL molecular subtypes that cut across traditional clinical and epidemiological categories and exhibit distinct biological profiles. In high-income countries (HICs), BL is highly curable with intensive multiagent chemotherapy and antibody-based therapy. In contrast, survival in sub-Saharan Africa rarely exceeds 50%, reflecting diagnostic delays, limited access to effective treatment, and challenges in supportive care. This review summarizes the advances in BL epidemiology, molecular biology, diagnosis, and treatment, highlighting how genomic insights have identified novel biomarkers for earlier detection and monitoring, as well as potential targeted therapies with reduced toxicity. These advances present opportunities to develop scalable diagnostic tools and tailored therapeutic strategies to narrow survival disparities, particularly in resource-limited settings, where most patients occur, and among adults and patients with relapsed or refractory BL in HICs. We also outline key unanswered questions in BL epidemiology and pathogenesis, discuss opportunities for translational research, and emphasize the need for improved model systems to study therapeutic resistance to close the survival gap.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6796-6811"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential mechanisms of statin and interferon-α2 therapy.","authors":"Isabella Diana Davidsen, Morten Kranker Larsen, Lea Löffler, Vibe Skov, Lasse Kjær, Christina Ellervik, Hans Carl Hasselbalch","doi":"10.1182/bloodadvances.2026021244","DOIUrl":"10.1182/bloodadvances.2026021244","url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"6849"},"PeriodicalIF":7.7,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}